Federal Court Upholds CollaGenex Classification As Antibiotic

Law360, New York (January 20, 2005, 12:00 AM EST) -- A federal court has upheld the U.S. Food and Drug Administration's classification of Periostat as an antibiotic drug, a decision that strips CollaGenex Pharmaceuticals Inc. of patent rights to the drug.

The drug maker vowed to seek “prompt injunctive relief” to protect its patent rights after the U.S. District Court for the District of Columbia upheld the FDA’s classification of Periostat as an antibiotic drug.

Under federal regulations, antibiotics are not entitled to the patent and exclusivity protection otherwise available under the Hatch Waxman amendments to...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.